Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors

Yongbae Kim, Jaeho Cho, Ki Chang Keum, Chang Geol Lee, Jinsil Seong, Chang-Ok Suh, Gwi Eon Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: To determine whether concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy is better than CCRT alone in the management of FIGO stage bulky IB and IIB uterine cervical cancer. Methods: Two hundred and five FIGO stage bulky IB and IIB patients with squamous cell carcinoma of the uterine cervix treated with CCRT were divided into 2 groups: (1) CCRT alone (n = 103, Group A) and (2) CCRT plus adjuvant chemotherapy (n = 102, Group B), and treatment outcomes were retrospectively compared between the two patient groups. Results: Only 63% of patients received all three planned cycles of adjuvant chemotherapy, while 16% received only one cycle because of increased treatment-related morbidity or other causes. There were no treatment-related deaths. Although 37 patients experienced failures after completion of treatment, no significant differences were found in patterns of local and regional failures between the two groups. The incidence of distant metastasis, including para-aortic or supraclavicular lymph node metastases, was not reduced in patients of Group B (8% in Group A vs. 7% in Group B). Overall five-year actuarial survival rates for Group A and Group B patients were 85% vs. 80%, and five-year disease-free survival rates were 83% vs. 78%, respectively. Conclusions: Our data failed to show discernable therapeutic advantage of adjuvant chemotherapy with given after CCRT for the management of FIGO stage bulky IB and IIB uterine cervical cancer patients. A future clinical trial will be necessary to test the clinical efficacy of the adjuvant treatment using newly developed agents in uterine cervical cancer patients.

Original languageEnglish
Pages (from-to)58-63
Number of pages6
JournalGynecologic Oncology
Volume104
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Chemoradiotherapy
Adjuvant Chemotherapy
Uterine Cervical Neoplasms
Survival Rate
Neoplasm Metastasis
Therapeutics
Cervix Uteri
Disease-Free Survival
Squamous Cell Carcinoma
Lymph Nodes
Clinical Trials
Morbidity
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

@article{8b048e8af5fa496e8feadfbffc50b86d,
title = "Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors",
abstract = "Objectives: To determine whether concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy is better than CCRT alone in the management of FIGO stage bulky IB and IIB uterine cervical cancer. Methods: Two hundred and five FIGO stage bulky IB and IIB patients with squamous cell carcinoma of the uterine cervix treated with CCRT were divided into 2 groups: (1) CCRT alone (n = 103, Group A) and (2) CCRT plus adjuvant chemotherapy (n = 102, Group B), and treatment outcomes were retrospectively compared between the two patient groups. Results: Only 63{\%} of patients received all three planned cycles of adjuvant chemotherapy, while 16{\%} received only one cycle because of increased treatment-related morbidity or other causes. There were no treatment-related deaths. Although 37 patients experienced failures after completion of treatment, no significant differences were found in patterns of local and regional failures between the two groups. The incidence of distant metastasis, including para-aortic or supraclavicular lymph node metastases, was not reduced in patients of Group B (8{\%} in Group A vs. 7{\%} in Group B). Overall five-year actuarial survival rates for Group A and Group B patients were 85{\%} vs. 80{\%}, and five-year disease-free survival rates were 83{\%} vs. 78{\%}, respectively. Conclusions: Our data failed to show discernable therapeutic advantage of adjuvant chemotherapy with given after CCRT for the management of FIGO stage bulky IB and IIB uterine cervical cancer patients. A future clinical trial will be necessary to test the clinical efficacy of the adjuvant treatment using newly developed agents in uterine cervical cancer patients.",
author = "Yongbae Kim and Jaeho Cho and Keum, {Ki Chang} and Lee, {Chang Geol} and Jinsil Seong and Chang-Ok Suh and Kim, {Gwi Eon}",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2006.07.005",
language = "English",
volume = "104",
pages = "58--63",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. / Kim, Yongbae; Cho, Jaeho; Keum, Ki Chang; Lee, Chang Geol; Seong, Jinsil; Suh, Chang-Ok; Kim, Gwi Eon.

In: Gynecologic Oncology, Vol. 104, No. 1, 01.01.2007, p. 58-63.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors

AU - Kim, Yongbae

AU - Cho, Jaeho

AU - Keum, Ki Chang

AU - Lee, Chang Geol

AU - Seong, Jinsil

AU - Suh, Chang-Ok

AU - Kim, Gwi Eon

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Objectives: To determine whether concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy is better than CCRT alone in the management of FIGO stage bulky IB and IIB uterine cervical cancer. Methods: Two hundred and five FIGO stage bulky IB and IIB patients with squamous cell carcinoma of the uterine cervix treated with CCRT were divided into 2 groups: (1) CCRT alone (n = 103, Group A) and (2) CCRT plus adjuvant chemotherapy (n = 102, Group B), and treatment outcomes were retrospectively compared between the two patient groups. Results: Only 63% of patients received all three planned cycles of adjuvant chemotherapy, while 16% received only one cycle because of increased treatment-related morbidity or other causes. There were no treatment-related deaths. Although 37 patients experienced failures after completion of treatment, no significant differences were found in patterns of local and regional failures between the two groups. The incidence of distant metastasis, including para-aortic or supraclavicular lymph node metastases, was not reduced in patients of Group B (8% in Group A vs. 7% in Group B). Overall five-year actuarial survival rates for Group A and Group B patients were 85% vs. 80%, and five-year disease-free survival rates were 83% vs. 78%, respectively. Conclusions: Our data failed to show discernable therapeutic advantage of adjuvant chemotherapy with given after CCRT for the management of FIGO stage bulky IB and IIB uterine cervical cancer patients. A future clinical trial will be necessary to test the clinical efficacy of the adjuvant treatment using newly developed agents in uterine cervical cancer patients.

AB - Objectives: To determine whether concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy is better than CCRT alone in the management of FIGO stage bulky IB and IIB uterine cervical cancer. Methods: Two hundred and five FIGO stage bulky IB and IIB patients with squamous cell carcinoma of the uterine cervix treated with CCRT were divided into 2 groups: (1) CCRT alone (n = 103, Group A) and (2) CCRT plus adjuvant chemotherapy (n = 102, Group B), and treatment outcomes were retrospectively compared between the two patient groups. Results: Only 63% of patients received all three planned cycles of adjuvant chemotherapy, while 16% received only one cycle because of increased treatment-related morbidity or other causes. There were no treatment-related deaths. Although 37 patients experienced failures after completion of treatment, no significant differences were found in patterns of local and regional failures between the two groups. The incidence of distant metastasis, including para-aortic or supraclavicular lymph node metastases, was not reduced in patients of Group B (8% in Group A vs. 7% in Group B). Overall five-year actuarial survival rates for Group A and Group B patients were 85% vs. 80%, and five-year disease-free survival rates were 83% vs. 78%, respectively. Conclusions: Our data failed to show discernable therapeutic advantage of adjuvant chemotherapy with given after CCRT for the management of FIGO stage bulky IB and IIB uterine cervical cancer patients. A future clinical trial will be necessary to test the clinical efficacy of the adjuvant treatment using newly developed agents in uterine cervical cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=33845968526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845968526&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.07.005

DO - 10.1016/j.ygyno.2006.07.005

M3 - Article

VL - 104

SP - 58

EP - 63

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -